retatrutide glp-1 gip glucagon agonist Synedica Buy Retatrutide Research Peptide |

In October 2024, the FDA announced that the shortage of tirzepatide, the active ingredient in Mounjaro and Zepbound, was resolved, and shortages of other GLP-1s are also poised to be resolved in the near future

Jascayd works by specifically inhibiting enzymes responsible for the fibrotic process in the lungs, potentially slowing disease progression and improving patient outcomes

[13] [1] Approved in November 2023, Zepbound represents a novel therapeutic approach to weight loss through its unique dual-receptor mechanism of action

However, not enough private insurers were willing to participate, so instead CMS is running an 18-month demonstration project (Bridge), where the obesity drugs are covered directly by the taxpayers and future Medicare premiums